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The regulation of human papillomavirus (HPV) gene expression by the E2 protein is a critical feature
of the viral life cycle. Previous studies have shown an important role in transcription for the ubiquitin-
proteasome pathway, but its role in HPV gene expression has not been addressed. We now show that HPV
E2 requires an active proteasome for its optimal transcriptional activator function. This involves an
interaction with the Mdm2 ubiquitin ligase, which together with E2 acts synergistically to activate the HPV
type 16 promoter. We also show that HPV E2 recruits Mdm2 onto HPV promoter sequences, providing an
explanation for this cooperative activity.
Viruses are intracellular parasites that rely upon their host
cells for the completion of their productive life cycles. There-
fore, viruses need to use cellular machinery to support their life
cycles. The replication of the double-stranded DNA genomes
of human papillomaviruses (HPVs) is directly regulated by the
viral helicase, E1, and the transcriptional regulator, E2 (19).
The E2 protein is a multifunctional, DNA binding protein,
consisting of a transactivation domain in the N-terminal half of
the protein, a middle nonconserved hinge region, and a C-
terminal domain that mediates DNA binding and protein
dimerization. Four E2 binding sites are present in the long
control regions (LCRs) of HPV genomes (30): two sites flank
the viral origin of replication, a third site lies directly upstream
of the early promoter which controls expression of viral early
genes (24, 27), and a fourth site lies at the 5 end of the LCR.
The binding of E2 to the LCR facilitates the binding of the E1
helicase to the viral origin of replication for the initiation of
DNA replication and the binding of transcription factors, such
as the TATA-binding protein and Sp1, that are required for
viral gene expression (29). In addition, a number of direct
interactions of E2 with cellular proteins such as Brd-4 (18),
TopBP1 (5), and Brm (11) further contribute to the regulation
of viral gene expression.
The role of the ubiquitin-proteasome machinery in tran-
scriptional regulation is now well recognized (20), although
how it functions most likely varies depending upon the precise
promoter complex. It may involve a form of licensing where
ubiquitination links the activities of specific transcription fac-
tors to their own destruction (26). Alternatively, ubiquitin-
modified transcription factors may recruit protein-remodeling
factors to the promoter and enhance corepressor/coactivator
exchange (7, 21). Specific examples of recruitment and en-
hancement include the regulation of gene expression by c-myc
and steroid hormone receptors (1, 23) as well as the activation
of the hTERT promoter by HPV E6, which is dependent on
the interaction between E6 and the E6AP ubiquitin ligase (15).
In the case of the HPV promoter and, more specifically, of
the function of E2, the involvement of the proteasome in
transcriptional regulation has not been documented. In order
to investigate this, we first analyzed the effects of proteasome
inhibition upon E2 transcriptional activity (8). To do this,
U2OS cells were transfected with an E2-responsive luciferase
reporter construct (p6xE2BS-Luc/E2-Luc reporter plasmid,
kindly provided by Ian Morgan) together with an untagged
HPV type 16 (HPV-16) E2 expression plasmid (22). After 24 h,
the cells were treated in the presence of 50 M of the protea-
some inhibitor CBZ (Sigma) or dimethyl sulfoxide, as a con-
trol, for a further 5 h. Then, the cells were lysed, and their
luciferase activity was determined using the Dual-Luciferase
assay kit (Promega). The results obtained are shown in Fig. 1a,
left panel, and demonstrate a clear inhibition of E2 transcrip-
tional activity following proteasome inhibition. To investigate
the specificity of proteasome inhibition on E2 transcriptional
activity, we also included a glucocorticoid receptor (GR)-re-
sponsive plasmid, MMTV-Luc (kindly provided by Olivier
Kassel [10]), which was shown previously to be unaffected by
proteasome inhibition (14). Figure 1a, right panel, shows that
CBZ did not suppress dexamethasone (Dex)-induced GR
transactivation. In the case of other transactivators, such as p53
and E2F, proteasome inhibition did affect their transcriptional
activity (data not shown), which is in agreement with previously
published data (13, 31).
Treatment with proteasome inhibitors is known to provide a
block to the entire proteasome machinery, but this result led us
to speculate whether or not a known ubiquitin ligase might be
involved in E2 transcriptional activity. We analyzed the effects
of a number of ubiquitin ligases that had previously been
linked to HPV function on E2 transcriptional activity. There-
fore, plasmids expressing E6/AP (kindly provided by Martin
Scheffner), Mdm2 (kindly provided by Claudio Schneider),
-TrCP (16), Smurf, and Cbl were cotransfected with E2 and
E2-Luc expression constructs, and luciferase assays were per-
formed after 24 h. The results obtained are shown in Fig. 1b,
where it can be seen that Mdm2 induces a dramatic increase in
the transcriptional activity of E2. In contrast, none of the other
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ubiquitin ligases had any significant effect on the ability of E2
to activate transcription, highlighting the specificity of the
Mdm2 activity with respect to E2. These results suggest that
the Mdm2 ubiquitin ligase activity might mediate this effect.
The C-terminal end of Mdm2 contains a RING domain
conferring E3 ligase activity which mediates its ability to target
several proteins for degradation, including p53 (2), pRb (28),
and the androgen receptor (9). In addition, the middle region
of Mdm2 also contains nuclear export and nuclear localization
sequences and was shown to increase the transcriptional activ-
ity of a number of factors such as the p53 homolog p63 (3) and
estrogen receptor  (25). To further investigate the role of
Mdm2 in the transcriptional activity of E2, we repeated the
luciferase assay using a point mutant of Mdm2 that no longer
has ubiquitin ligase enzymatic activity (Mdm2C462A; kindly
provided by Claudio Schneider) and including proteasome in-
hibition as an additional control. Figure 2a shows again that
Mdm2 exerts a potent stimulatory effect upon E2 transcrip-
tional activity and that this is abolished following treatment
with CBZ. Most importantly, the Mdm2C462A mutant is also
defective in its ability to stimulate E2 transcriptional activity,
demonstrating that Mdm2 ubiquitin ligase activity is required
for its ability to upregulate the E2 transcriptional activator
function.
To exclude a possible indirect role for p53 in these assays,
the same experiment was repeated with SAOS-2 cells (p53/
pRb/) and H1299 cells (p53/). Figure 2b shows that
Mdm2 cooperates with the transcriptional activation function
of E2 in both cell lines, demonstrating that this is independent
of Mdm2’s ability to degrade either p53 or pRb. Furthermore,
expression of Mdm2 in increasing amounts in H1299 cells
resulted in a progressive increase in the transcriptional activity
of E2 (Fig. 2b, right), demonstrating that Mdm2 cooperates
with E2’s transcriptional transactivation function in a dose-
dependent manner. We also tested whether inhibiting the ac-
tivity of endogenous Mdm2 would affect the transcriptional
activity of E2. To do this, SAOS-2 cells transfected with E2 and
E2-Luc plasmids were treated with two different Mdm2 inhib-
itors, Nutlin-3 and Mdm2 E3 ligase inhibitor, which were used
previously to inhibit Mdm2 functions that are independent of
p53 degradation (4). The results obtained are shown in Fig. 2c,
where it can be seen that inhibiting endogenous Mdm2 activity
by either inhibitor results in a decrease in E2’s transcriptional
activity. Finally, we also wished to determine whether or not
FIG. 1. The role of the proteasome machinery in the transcriptional activity of E2. To assess E2 transcriptional activity, luciferase assays were
conducted in U2OS cells transfected with a reporter construct containing E2 binding sites upstream of the luciferase gene (E2-Luc), plus the
Renilla luciferase gene as a transfection control and an untagged HPV-16 E2 expression plasmid. Representative results of three experiments are
shown together with standard deviations. RLA, relative luciferase activity. (a, left) E2 transcriptional activity in the presence or absence of
proteasome inhibitors (CBZ). (a, right) The effects of CBZ on Dex-induced GR transactivation. U2OS cells were transfected with GR and
MMTV-Luc plasmids and treated with 10 nM Dex (Sigma) for 16 h, followed by treatment with CBZ for a further 5 h. (b) The effects of various
ubiquitin ligases on E2 transcriptional activity. Cells were transfected with the reporter plasmids and E2 in the presence of expression plasmids
of the indicated ubiquitin ligases.
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Mdm2 can affect the levels of E2 protein expression. To do
this, U2OS cells were transfected with the E2 expression plas-
mid together with Mdm2 and a -galactosidase (-Gal) marker
for transfection efficiency, and 24 h later, the levels of E2
expression were ascertained by Western blot analysis using
polyclonal anti-E2 antibodies (17). The results in Fig. 2d show
that the levels of E2 remain largely unchanged with respect to
the -Gal loading control in the presence of Mdm2. This dem-
onstrates that the increased transcriptional activation exhibited
by E2 in the presence of Mdm2 is not the result of increased
levels of E2 expression. Taken together, these results demon-
strate that E2 requires the functional proteasome machinery
for optimal transcriptional activity and that this appears to
involve the Mdm2 ubiquitin ligase.
Since we had seen that Mdm2 affects E2 transcriptional
activity without affecting its protein expression levels, we then
sought to examine whether Mdm2 and E2 can interact. Using
an in vitro binding assay, bacterially expressed glutathione
S-transferase (GST) fusion proteins (6) were incubated with in
vitro translated and radiolabeled Mdm2 (as described in ref-
erence 8). Figure 3a shows that Mdm2 can bind to GST-16E2,
albeit less strongly than it binds to GST-p53; no binding is seen
with GST alone. To identify the region of E2 that mediates its
interaction with Mdm2, we used a number of GST-tagged E2
fragments, including the N- and C-terminal domains and trun-
cation fragments of the C-terminal domain (Fig. 3b, right).
These were previously described in reference 6. Figure 3b
shows that E2 binds to Mdm2 mainly through its C-terminal
half and, more specifically, through a region spanning amino
acid residues 322 to 335.
In order to verify that E2 and Mdm2 can form a complex in
vivo, we performed a coimmunoprecipitation assay with 293
cells that were transfected with either Mdm2 alone or Mdm2
plus GFP-tagged E2. At 24 h posttransfection, E2 was immu-
noprecipitated from cell extracts, using antibodies against
green fluorescent protein (GFP) (polyclonal; Santa Cruz), for
3 to 4 h. After extensive washing, the immunoprecipitate was
analyzed by Western blotting, using an anti-Mdm2 monoclonal
antibody (kindly provided by Giannino Del Sal). Figure 3c
shows that a complex between Mdm2 and E2 can be detected
FIG. 2. Mdm2 enhances the transcriptional activity of E2. (a) The ubiquitin ligase activity of Mdm2 is required to enhance E2 transcriptional
activity. A luciferase assay was conducted in the presence of Mdm2C462A (ligase-dead mutant of Mdm2) and CBZ. RLA, relative luciferase
activity. (b) Mdm2 enhances E2-mediated transcriptional activity in SAOS-2 (p53/ pRb/) (left panel) and H1299 (p53/ pRb/) (right
panel) cells. Cells were transfected with the reporter construct and an E2 expression vector with or without the expression of Mdm2 as shown in
panel a. (c) The transcriptional activity of E2 is reduced in the presence of Mdm2 inhibitors. SAOS-2 cells were transfected as shown in panel b.
Five hours prior to harvest, cells were treated with Nutlin-3 (10 M; Sigma) or Mdm2 E3 ligase inhibitor (10 M; Calbiochem). (d) The effect
of Mdm2 expression on E2 levels was tested by expressing both proteins in U2OS cells. At 24 h after transfection, protein levels were analyzed
by Western blotting using antibodies against 16E2 or -Gal as a transfection control.
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in cells expressing Mdm2 and E2 but not in cells expressing
Mdm2 alone, demonstrating that E2 and Mdm2 can form a
complex in vivo.
Since the recruitment of ubiquitin ligases to promoters is
one means by which the proteasome can be linked directly to
transcriptional activation, we examined whether E2 could sim-
ilarly recruit Mdm2 to the HPV promoter by using a chromatin
immunoprecipitation assay (Upstate Biotechnology). 293 cells
were transfected with the E2-Luc construct together with
GFP-E2 and FLAG-Mdm2 expression constructs (kindly pro-
vided by Ian Morgan and Giannino Del Sal, respectively). At
24 h posttransfection, cells were cross-linked with 1% formal-
dehyde for 10 min at 37°C, lysed, and sonicated to generate
200- to 1,000-bp DNA fragments. Cell lysates were then incu-
bated with the indicated antibodies, and immunoprecipitated
complexes were analyzed by PCR to detect protein interaction
with DNA. Initially, we verified that GFP-E2 and FLAG-
Mdm2 could form a complex in vivo by using anti-FLAG an-
tibodies (M2; Sigma) to immunoprecipitate Mdm2, followed
by Western blot analysis using anti-E2 antibodies (17). The
results in Fig. 4a again confirm the binding of both proteins in
vivo. In parallel, cell extracts were immunoprecipitated using
anti-GFP (Clontech), anti-FLAG (Sigma), or anti-HA
(Roche) antibodies, and the coprecipitated DNA was analyzed
by PCR using primers complementary to sequences present in
the luciferase gene (12). The results in Fig. 4b show that, as
expected, GFP-E2 binds strongly to DNA that contains E2
binding sites (lane 5). Interestingly, by using anti-FLAG anti-
bodies, we see that Mdm2 coimmunoprecipitates with DNA in
the presence of E2 (Fig. 4b, lane 6); in contrast, there is no
coimmunoprecipitation of DNA in the absence of E2 (Fig. 4b,
lanes 1 through 3) nor when using anti-HA antibodies as a
control (Fig. 4b, lane 4). These results strongly suggest that
Mdm2 can bind to E2 when it is bound to its cognate DNA
recognition sequences.
This study shows for the first time a role for a ubiquitin
ligase, Mdm2, in the transcriptional activity of HPV-16 E2.
This observation is supported by the abilities of Mdm2 and
E2 to interact in vivo and in vitro. The effects of Mdm2 on E2
transcriptional activity are not due to alterations in the protein
levels of E2 but most probably due to the ability of E2 to
recruit Mdm2 to the HPV promoter. The exact molecular
mechanisms by which Mdm2 influences the transcriptional ac-
tivity of E2 are still to be identified. Mdm2 may increase the
ubiquitination of E2, it might modulate the recruitment of
cellular factors that may facilitate E2 transcriptional activ-
ity, or it may direct the degradation of some of the tran-
scriptional machinery, thereby allowing increased transcrip-
tional licensing and processivity. At present we cannot
completely differentiate between these different possibili-
ties; however, a role in transcriptional licensing seems to be
most likely. Clearly, an active proteasome is required, which
FIG. 3. Mdm2 interacts with 16E2 in vitro and in vivo. (a) In vitro-translated and radiolabeled Mdm2 was incubated with bacterially purified
GST-tagged E2. GST alone and GST-p53 were included as negative and positive controls, respectively. Bound proteins were analyzed using sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and autoradiography. The Coomassie blue stains of the GST inputs are also included in the top
panel. An asterisk indicates the full-length GST fusion proteins. (b) Mdm2 binds to the C-terminal region of E2. GST-16E2 and a number of
GST-tagged fragments of E2 (right) were incubated with in vitro-translated and radiolabeled Mdm2, and bound proteins were analyzed using
sodium dodecyl sulfate-polyacrylamide gel electrophoresis and autoradiography. Fifty percent of the input is included, and the GST inputs are
shown in the bottom panel and are stained with Coomassie blue. An asterisk indicates the full-length GSTs. NE2, N-terminal half of E2 protein;
CE2, C-terminal half of E2 protein. (c) E2 and Mdm2 bind in vivo. 293 cells were transfected using either Mdm2 alone or Mdm2 with
GFP-tagged E2. Cell extracts were immunoprecipitated (IP) using polyclonal anti-GFP antibodies, followed by Western blot analysis using
antibodies against Mdm2 or GFP. An asterisk indicates nonspecific bands. -ve, untransfected cells.
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tends to rule out the simple ubiquitin modification of E2 and
suggests rather that the proteolytic machinery is involved. In
addition, a mutant Mdm2 lacking ubiquitin ligase activity is
unable to increase E2 transcriptional activation, and two
small molecule inhibitors of Mdm2 also reduce E2 transcrip-
tional activity, thereby demonstrating that the ubiquitin li-
gase activity of Mdm2 is also important. Finally, a clear
complex between E2 and Mdm2 is seen when E2 is bound to
its cognate DNA recognition sequence, demonstrating that
E2 can actively recruit Mdm2 to the HPV promoter. Com-
bining these three critical features supports a role for Mdm2
in the transcriptional licensing of HPV-16 E2-activated gene
expression. Future studies will now aim to identify the sub-
strates of this E2/Mdm2/DNA complex.
This work was supported in part by a research grant from the
Associazione Italiana per la Ricerca sul Cancro.
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